The Food and Drug Administration (FDA or Agency) is amending its regulations to update the address for applicants to submit investigational new drug applications (INDs) for biological products regulated by the Center for Drug Evaluation and Research (CDER). FDA is also amending its regulations on the criteria and evidence to assess actual and potential bioequivalence problems (bioequivalence regulations) to correct a typographical error. FDA is taking this action to ensure accuracy and clarity in the Agency's regulations.
Document
Investigational New Drug Applications for Biological Products; Bioequivalence Regulations; Technical Amendment
The Food and Drug Administration (FDA or Agency) is amending its regulations to update the address for applicants to submit investigational new drug applications (INDs) for biol...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
81 FR 17065
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Investigational New Drug Applications for Biological Products; Bioequivalence Regulations; Technical Amendment,” thefederalregister.org (March 28, 2016), https://thefederalregister.org/documents/2016-06886/investigational-new-drug-applications-for-biological-products-bioequivalence-regulations-technical-amendment.